These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37731423)
1. Acute Pancreatitis in a Patient Taking Semaglutide. Patel F; Gan A; Chang K; Vega KJ Cureus; 2023 Aug; 15(8):e43773. PubMed ID: 37731423 [TBL] [Abstract][Full Text] [Related]
2. Safety of Semaglutide. Smits MM; Van Raalte DH Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810 [TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Nauck MA; Quast DR; Wefers J; Meier JJ Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776 [TBL] [Abstract][Full Text] [Related]
4. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? Doggrell SA Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603 [TBL] [Abstract][Full Text] [Related]
5. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Brunton SA; Mosenzon O; Wright EE Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985 [TBL] [Abstract][Full Text] [Related]
8. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Tuchscherer RM; Thompson AM; Trujillo JM Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244 [TBL] [Abstract][Full Text] [Related]
10. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961 [TBL] [Abstract][Full Text] [Related]
11. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Aroda VR; Erhan U; Jelnes P; Meier JJ; Abildlund MT; Pratley R; Vilsbøll T; Husain M Diabetes Obes Metab; 2023 May; 25(5):1385-1397. PubMed ID: 36700417 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Feng Z; Tong WK; Zhang X; Tang Z Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313 [No Abstract] [Full Text] [Related]
14. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418 [TBL] [Abstract][Full Text] [Related]
15. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. Goldenberg RM; Steen O Can J Diabetes; 2019 Mar; 43(2):136-145. PubMed ID: 30195966 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. Alhindi Y; Avery A Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819 [TBL] [Abstract][Full Text] [Related]
17. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Patel D J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489 [TBL] [Abstract][Full Text] [Related]
18. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Wright EE; Aroda VR Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423 [TBL] [Abstract][Full Text] [Related]
19. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Liu L; Chen J; Wang L; Chen C; Chen L Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085 [TBL] [Abstract][Full Text] [Related]
20. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? Kim HS; Jung CH Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]